Gland Pharma Shares Rise to 52-Week High on Strong Q2 Revenue and Profit Growth
Gland Pharma shares reached a 52-week high during Monday's trading, rising over 6.7% despite a broader market decline. The stock gained momentum following the company's strong Q2 FY27 results, which showed a 23% year-on-year revenue increase to Rs 1,834 crore and a 58% rise in net profit to Rs 290.8 crore. Growth was driven by the CDMO and Critical Injectables segments, alongside increased R&D investment and new product launches in the US market.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (65/100). Lens Score 31/100.
Outlets measured: economictimes, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 9 Nov, 04:50 am. Other outlets followed.